Herpes Simplex Virus Type 1 and/or 2 Antibodies, IgG, CSF
0050394
Ordering Recommendation
For suspected and/or active herpes simplex virus (HSV) infection, molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)). If pursuing antibody testing, refer to Herpes Simplex Virus Type 1 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF (0050379) and Herpes Simplex Virus Type 2 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF (0050359). If acute HSV infection is suspected, molecular testing is preferred (refer to Herpes Simplex Virus by PCR (0060041)).
Mnemonic
HER1/2CSF
Methodology
Semi-Quantitative Chemiluminescent Immunoassay
Performed
Sun-Sat
Reported
Within 24 hours
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
- Patient Preparation
- Collect
- CSF.
- Specimen Preparation
- Transfer 1 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Specimens types other than CSF. Contaminated, heat-inactivated or hemolyzed specimens.
- Remarks
- Indicate source on test request form.
- Stability
- Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 year
Reference Interval
0.89 IV or less: Negative - No significant level of detectable HSV IgG antibody.
0.90-1.09 IV: Equivocal - Questionable presence of IgG antibodies. Repeat testing in 10-14 days may be helpful.
1.10 IV or greater: Positive - IgG antibody to HSV detected which may indicate a current or past HSV infection.
0.90-1.09 IV: Equivocal - Questionable presence of IgG antibodies. Repeat testing in 10-14 days may be helpful.
1.10 IV or greater: Positive - IgG antibody to HSV detected which may indicate a current or past HSV infection.
Interpretive Data
The detection of antibodies to herpes simplex virus in CSF may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.
Fourfold or greater rise in CSF antibodies to herpes on specimens at least 4 weeks apart are found in 74-94% of patients with herpes encephalitis. Specificity of the test based on a single CSF testing is not established. Presently PCR is the primary means of establishing a diagnosis of herpes encephalitis.
Fourfold or greater rise in CSF antibodies to herpes on specimens at least 4 weeks apart are found in 74-94% of patients with herpes encephalitis. Specificity of the test based on a single CSF testing is not established. Presently PCR is the primary means of establishing a diagnosis of herpes encephalitis.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0050394 | HSV 1/2 Antibody Screen IgG, CSF | 13249-8 |
Aliases
- Herpes Simplex Antibodies, IgG
- Herpes Simplex Serology, Serum HSV 1,2
- HSV 1, 2 IgG
- HSV 1,2
- HSV CSF IgG